- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-SLC35F2
SLC35F2 Polyclonal Antibody for WB, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, souris
Applications
WB, IP, ELISA
Conjugaison
Non conjugué
N° de cat : 25526-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules A549, tissu cérébral de souris |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 1 publications below |
| WB | See 5 publications below |
| IP | See 1 publications below |
Informations sur le produit
25526-1-AP cible SLC35F2 dans les applications de WB, IP, ELISA et montre une réactivité avec des échantillons Humain, souris
| Réactivité | Humain, souris |
| Réactivité citée | Humain |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Polyclonal |
| Type | Anticorps |
| Immunogène | SLC35F2 Protéine recombinante Ag20901 |
| Nom complet | solute carrier family 35, member F2 |
| Masse moléculaire calculée | 374 aa, 41 kDa |
| Poids moléculaire observé | 41-50 kDa |
| Numéro d’acquisition GenBank | BC039195 |
| Symbole du gène | SLC35F2 |
| Identification du gène (NCBI) | 54733 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par affinité contre l'antigène |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
SLC35F2, also named as Solute carrier family 35 member F2, is a 374 amino acid protein, which belongs to the SLC35F solute transporter family. SLC35F2 as a Multi-pass membrane protein is a putative solute transporter. SLC35F2 is highly homologous to the lung squamous cell cancer-related gene, LSCC3, which is highly expressed in lung squamous cell tumour tissues. However, the clinical implication of the SLC35F2 gene in tumour development and progression remains unclear.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for SLC35F2 antibody 25526-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Theranostics USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2 | ||
Mol Cancer Res Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. | ||
Biochem Biophys Res Commun βTrCP1 promotes SLC35F2 protein ubiquitination and inhibits cancer progression in HeLa cells | ||
Onco Targets Ther Knockdown of SLC35F2 Inhibits the Proliferation and Metastasis of Bladder Cancer Cells.
| ||
Biochim Biophys Acta Gen Subj E3 ubiquitin ligase APC/CCdh1 regulates SLC35F2 protein turnover and inhibits cancer progression in HeLa cells |

